Nastya Kassir

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Ulcerative Colitis

Monoclonal Antibody

Top Venues

CPT: pharmacometrics & systems pharmacology

Journal of clinical pharmacology

Clinical and translational science

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun Kumar, Ahmadur Rahman, Thorsten Ruf, Sravanthi Cheeti, Wendy Ankrom
Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. Journal of clinical pharmacology (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun Kumar, Ahmadur Rahman, Thorsten Ruf, Sravanthi Cheeti, Wendy Ankrom
Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. Journal of clinical pharmacology 64 (6) (2024)
Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun Kumar, Ahmadur Rahman, Thorsten Ruf, Sravanthi Cheeti, Wendy Ankrom
Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. Journal of clinical pharmacology 64 (6) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. CPT: pharmacometrics & systems pharmacology (2024)
Nastya Kassir, Phyllis Chan, Steve Dang, René Bruno
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data. Cancer chemotherapy and pharmacology (2023)
Rashed Harun, James Lu, Nastya Kassir, Wenhui Zhang
Machine Learning-based Quantification of Patient Factors Impacting Remission in Patients with Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials. Clinical pharmacology and therapeutics (2023)
Anita Moein, Jurgen Langenhorst, Elodie L Plan, Jin Y Jin, Matts Kågedal, Nastya Kassir
A Disease Model Predicting Placebo Response and Remission Status of Patients with Ulcerative Colitis Using Modified Mayo Score. Clinical and translational science (2023)
Nastya Kassir, Rui Zhu, Anita Moein, Jurgen Langenhorst, Jakob Ribbing, Rong Zhang, Meina T Tang, Young S Oh, Wenhui Zhang
Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Anita Moein, Tong Lu, Siv Jonsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina T Tang, Young S Oh, René Bruno, Rui Zhu
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Yukari Okubo, Mamitaro Ohtsuki, Mayumi Komine, Shinichi Imafuku, Nastya Kassir, Rosemary Petric, Osamu Nemoto
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis. The Journal of dermatology 48 (11) (2021)
Yi Wang, Jean-Francois Marier, Nastya Kassir, Colin Chang, Patrick Martin
Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema. Clinical and translational science 13 (6) (2020)